A new study of WHO has found that remdesivir drug has little role to recover patients from COVID-19 ‘very little or no impact on survival relatively long.
The World Health Organization (WHO) has evaluated trials of four possible drugs of Covid-19, including remdesivir and hydroxychloroquine.
One of the first drugs used in the treatment of coronavirus is remdesivir. Remdesivir drugs were also used to treat US President Donald Trump’s body. While he was hospitalized to affected COVID-19.
The drug manufacturer, Gilead Sciences has withdrawn the World Health Organization’s claim.
A statement from Gilead said that the data from the study were “inconsistent” with other studies and that they were “concerned” about whether the results of a recent study had been reviewed.
For the Solidarity Clinical Trial, the World Health Organization tested the efficacy of four potential drugs – the Ebola drug remdesivir, the malaria drug hydroxychloroquine, the autoimmune drug interferon, and the lopinavir and ritonavir used as HIV drugs.
Dexamethasone, a low-cost steroid used in patients with coronavirus in the ICU of the United Kingdom, was not included in the study.
Four drug tests were performed on 11,266 adult patients in a total of 500 hospitals in more than 30 countries.
‘A peer review of the results of the study or a comparative review with research on a similar topic has not yet been completed. But the World Health Organization says there is not enough evidence so far that any of these four drugs have a role in preventing COVID-19 patients’ deaths or influencing hospital stays.
Saumya Swaminathan the chief scientist at the World Health Organization said on Wednesday that trials of hydroxychloroquine and lopinavir/ritonavir were halted in June because they proved to be ineffective. However, trials of other drugs were going on.
The results of a recent study conducted by the World Health Organization contradict the results of a study conducted by Gilead earlier this month.
The Gilead study found that the use of remdesivir drug in COVID-19 patients in the ICU could reduce hospital stay by five days.
About a thousand COVID-19 patients took part in that trial in Gilead.
Gilead Sciences, the pharmaceutical company of remdesivir has rejected a research report by the World Health Organization.
“Recent data from the World Health Organization (WHO) is inconsistent. A randomized controlled research report published in multiple peer-reviewed journals raises the issue of the benefits of treatment with remdesivir,” the organization said in a statement.
“I’m concerned that this open-label global trial did not go through the necessary reviews, leading to its constructive scientific criticism.”